482 related articles for article (PubMed ID: 19157433)
1. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
[TBL] [Abstract][Full Text] [Related]
2. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
[TBL] [Abstract][Full Text] [Related]
3. The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: implications for treatment selection.
Gao X; Mohideen N; Flanigan RC; Waters WB; Wojcik EM; Leman CR
J Urol; 2000 Dec; 164(6):1982-6. PubMed ID: 11061896
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF
Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843
[TBL] [Abstract][Full Text] [Related]
5. Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.
Sankin A; Tareen B; Lepor H
Prostate Cancer Prostatic Dis; 2009; 12(2):204-8. PubMed ID: 19238170
[TBL] [Abstract][Full Text] [Related]
6. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract][Full Text] [Related]
8. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer.
Teloken C; Da Ros CT; Caraver F; Weber FA; Cavalheiro AP; Graziottin TM
J Urol; 2005 Dec; 174(6):2178-80. PubMed ID: 16280759
[TBL] [Abstract][Full Text] [Related]
9. Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination.
Tsuzuki T; Hernandez DJ; Aydin H; Trock B; Walsh PC; Epstein JI
J Urol; 2005 Feb; 173(2):450-3. PubMed ID: 15643200
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
Malaeb BS; Rashid HH; Lotan Y; Khoddami SM; Shariat SF; Sagalowsky AI; McConnell JD; Roehrborn CG; Koeneman KS
Urol Oncol; 2007; 25(4):291-7. PubMed ID: 17628294
[TBL] [Abstract][Full Text] [Related]
11. Preoperative serum sex hormone-binding globulin as a predictive marker for extraprostatic extension of tumor in patients with clinically localized prostate cancer.
Lee SE; Chung JS; Han BK; Park CS; Moon KH; Byun SS; Choe G; Hong SK
Eur Urol; 2008 Dec; 54(6):1324-32. PubMed ID: 18339472
[TBL] [Abstract][Full Text] [Related]
12. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy.
Moul JW; Maygarden SJ; Ware JL; Mohler JL; Maher PD; Schenkman NS; Ho CK
J Urol; 1996 Mar; 155(3):982-5. PubMed ID: 8583622
[TBL] [Abstract][Full Text] [Related]
14. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy.
Shariat SF; Khoddami SM; Saboorian H; Koeneman KS; Sagalowsky AI; Cadeddu JA; McConnell JD; Holmes MN; Roehrborn CG
J Urol; 2004 Mar; 171(3):1122-7. PubMed ID: 14767284
[TBL] [Abstract][Full Text] [Related]
15. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Kumano M; Miyake H; Muramaki M; Furukawa J; Takenaka A; Fujisawa M
Urol Oncol; 2009; 27(2):180-6. PubMed ID: 18439850
[TBL] [Abstract][Full Text] [Related]
16. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
Adler HL; McCurdy MA; Kattan MW; Timme TL; Scardino PT; Thompson TC
J Urol; 1999 Jan; 161(1):182-7. PubMed ID: 10037394
[TBL] [Abstract][Full Text] [Related]
17. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
Hong SK; Han BK; Jeong JS; Jeong SJ; Moon KH; Byun SS; Lee SE
Asian J Androl; 2008 Mar; 10(2):207-13. PubMed ID: 18097534
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms.
Shariat SF; Park S; Trinh QD; Roehrborn CG; Slawin KM; Karakiewicz PI
J Urol; 2007 Oct; 178(4 Pt 1):1229-36; discussion 1236-7. PubMed ID: 17698116
[TBL] [Abstract][Full Text] [Related]
19. Ultrasound-guided seminal vesicle biopsies in prostate cancer.
Wymenga LF; Duisterwinkel FJ; Groenier K; Mensink HJ
Prostate Cancer Prostatic Dis; 2000 Aug; 3(2):100-106. PubMed ID: 12497106
[TBL] [Abstract][Full Text] [Related]
20. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer.
Shariat SF; Bensalah K; Karam JA; Roehrborn CG; Gallina A; Lotan Y; Slawin KM; Karakiewicz PI
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5377-84. PubMed ID: 17875766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]